Top

BY Lany Kimmons

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon form of ALCL that was first reported in 1996. The U.S. Food and Drug Administration (FDA) first reported a possible link between women with breast implants and ALCL in 2011, based on its investigation of 34 published reports of ALCL.

BIA-ALCL typically develops in the fluid and the capsule around a textured surface breast implant with the most common...

Breast implant-associated anaplastic large cell lymphoma expert Mark Clemens, M.D., holds a textured breast implant.

BY Clayton Boldt, Ph.D.

Chimeric antigen receptor (CAR) T cells were approved by the Food and Drug Administration (FDA) to treat relapsed and refractory large B-cell...

BY Ron Gilmore

Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...

BY Ron Gilmore

Tomas Sandoval was about to become a father for the second time in June 2014, when he was devastated to learn he had non-Hodgkin lymphoma, a type of cancer that starts in the white blood cells. The College Station, Texas, resident underwent a stem cell transplant at MD Anderson that kept his disease in check – for a year.

In June 2015, doctors discovered a large chest mass that revealed Sandoval’s cancer had spread...

Naval Daver, M.D., leukemia

BY Scott Merville

Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping...

BY Sarah Bronson

Two new clinical trials at MD Anderson are taking aim at mantle cell lymphoma – a rare form of non-Hodgkin’s lymphoma.

Most mantle...

BY Scott Merville

MD Anderson’s Moon Shots Program has expanded its targets, adding some of the most intractable cancers to its campaign to more rapidly convert...

BY Clayton Boldt, Ph.D.

The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...

BY Ron Gilmore

Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T...